Bordeaux, Boston, July 7, 2020 – 5.45 pm CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral andknee-surgery implants, today announces its revenue for the first half of 2020.
Impact of the Covid-19 pandemic:
To provide greater clarity regarding the impact of the Covid-19 pandemic, Implanet has chosen to indicate the percentage of 2019 monthly revenue achieved in each of the first six months of 2020.
Ludovic Lastennet, CEO of Implanet, says: “In recent months, activity has understandably been affected by the public health emergency associated with the Covid-19 pandemic. It is encouraging that June saw a significant upturn in our sales momentum. This trend is in line with the performance recorded last year over the same period, and direct Spine activity even exceeded forecast in France. This leads us to believe that the gradual resumption in activity should continue over the coming months. We remain cautious, of course, and are closely monitoring the health situation in the countries in which we operate. However, our confidence remains high given the quality of our product ranges and our long-term regulatory strategy. During this unprecedented period, Implanet has shown agility by adapting its cost structure and by being pragmatic in the way it has managed its operations. Our cash position is secure thanks to the measures taken and the assistance received to date, we are positioned to make the most of the recovery as it progresses”.
Upcoming financial events:
– H1 2020 results, September 15, 2020 after market close
– Q3 2020 revenue, October 13, 2020 after market close
About Implanet
Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around two product ranges, the latest generation JAZZ® implant, designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery, and the MADISON implant designed for first-line prosthetic knee surgery. Implanet’s tried-and-tested orthopedic platform is based on product traceability. Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark as well as the ANVISA authorization in Brazil. Implanet employs 36 staff and recorded 2019 sales of €7.4 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80
NEWCAP
Sandrine Boussard-Gallien
Investor relations
Phone nb.: 01 44 71 20 40
Email: [email protected]
IMPLANET
Ludovic Lastennet
CEO
Phone nb.: 05 57 99 55 55
Email: [email protected]
NEWCAP
Nicolas Merigeau
Media Relations
Phone nb.: 01 44 71 94 98
Email: [email protected]